

Loss of Antiâ€“SARS-CoV-2 Antibodies in Mild Covid-19

New England Journal of Medicine

383, 1694-1698

DOI: [10.1056/nejmc2027051](https://doi.org/10.1056/nejmc2027051)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Not just antibodies: B cells and T cells mediate immunity to COVID-19. <i>Nature Reviews Immunology</i> , 2020, 20, 581-582.	10.6	239
2	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	1.6	39
3	Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 90, 107271.	1.7	36
4	Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review. <i>Vaccines</i> , 2021, 9, 102.	2.1	28
5	Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
6	Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. <i>Transfusion</i> , 2021, 61, 1148-1159.	0.8	11
7	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
10	Decline and loss of SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. <i>Kidney International</i> , 2021, 99, 486-488.	2.6	30
11	Why current quantitative serology is not quantitative and how systems immunology could provide solutions. <i>Biologia Futura</i> , 2021, 72, 37-44.	0.6	6
12	Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study. <i>BMJ Open</i> , 2021, 11, e044552.	0.8	6
14	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	2.1	12
15	Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. <i>Med</i> , 2021, 2, 281-295.e4.	2.2	153
16	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	1.6	14
17	Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1835-1844.	1.4	27
19	Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2021, 224, 983-988.	1.9	65
20	Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 123-129.	0.1	1
21	Two SARS-CoV-2 IgG immunoassays comparison and time-course profile of antibodies response. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115297.	0.8	9
22	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	2.6	32

#	ARTICLE	IF	CITATIONS
23	Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK. <i>Emerging Infectious Diseases</i> , 2021, 27, 1155-1158.	2.0	13
24	Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure. <i>Journal of Clinical Medicine</i> , 2021, 10, 1968.	1.0	10
25	Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	18
27	Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. <i>Diagnostics</i> , 2021, 11, 995.	1.3	16
28	Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. <i>PLoS ONE</i> , 2021, 16, e0252628.	1.1	11
29	Retrospective of International Serological Studies on the Formation and Dynamics of the Humoral Immune Response to SARS-CoV-2: from 2020 to 2021. <i>Acta Biomedica Scientifica</i> , 2021, 6, 47-57.	0.1	4
30	The First Case of Immunity Loss and SARS-CoV-2 Reinfection by the Same Virus Lineage in Amazonia. <i>Journal of Racial and Ethnic Health Disparities</i> , 2021, 8, 821-823.	1.8	9
31	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
32	Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19. <i>Transplant Infectious Disease</i> , 2021, 23, e13646.	0.7	8
33	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	7.3	60
34	Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 808-813.	0.8	20
35	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. <i>BMC Infectious Diseases</i> , 2021, 21, 580.	1.3	20
36	A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. <i>EClinicalMedicine</i> , 2021, 36, 100902.	3.2	85
37	Indicators of the Immune Status in Children after a New Coronavirus Infection. <i>Acta Biomedica Scientifica</i> , 2021, 6, 58-62.	0.1	2
39	Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2. <i>Clinical Infectious Diseases</i> , 2022, 74, 1220-1229.	2.9	45
40	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1063-1067.	0.8	9
41	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	1.0	53
42	Risk factors and predictors that influence SARS-Cov-2 IgG positivity. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2021, 42, 853-861.	0.5	2

#	ARTICLE	IF	CITATIONS
45	Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods. <i>Diagnostics</i> , 2021, 11, 1709.	1.3	8
46	Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 112, 103-110.	1.5	11
47	Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection. <i>Clinical Immunology</i> , 2021, 230, 108814.	1.4	26
48	Brazil's COVID-19 Epicenter in Manaus: How Much of the Population Has Already Been Exposed and Are Vulnerable to SARS-CoV-2?. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 2098-2104.	1.8	7
49	Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2307-2310.	2.6	20
50	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <i>Science China Life Sciences</i> , 2020, 63, 1833-1849.	2.3	29
56	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	1.5	26
57	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
58	Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020. <i>International Journal of Infectious Diseases</i> , 2022, 114, 21-28.	1.5	29
59	Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. <i>Heliyon</i> , 2021, 7, e08140.	1.4	7
60	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	2.2	25
61	A Case of Suspected Tuberculous Pleurisy and Coronavirus Disease 2019 Comorbidity. <i>Internal Medicine</i> , 2022, 61, .	0.3	1
62	Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea. <i>PLoS ONE</i> , 2022, 17, e0262820.	1.1	1
63	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	1.0	8
64	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0265621.	1.8	14
66	Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave. <i>Preventive Medicine Reports</i> , 2022, 26, 101752.	0.8	8
67	Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. <i>Viruses</i> , 2022, 14, 758.	1.5	4
68	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. <i>Antiviral Research</i> , 2022, 201, 105297.	1.9	3

#	ARTICLE	IF	CITATIONS
69	The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production. <i>Scientific Reports</i> , 2021, 11, 23713.	1.6	11
70	SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: Cross-sectional study. <i>Health Science Reports</i> , 2022, 5, e634.	0.6	2
71	Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus. <i>PLoS ONE</i> , 2022, 17, e0269885.	1.1	2
72	The potential of developing a protective peptide-based vaccines against SARS-CoV-2. <i>Drug Development Research</i> , 0, , .	1.4	2
73	ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	41
74	Evaluation of the performance of multiple immunoassay diagnostic platforms on the National Microbiology Laboratory SARS-CoV-2 National Serology Panel. <i>Jammi</i> , 0, , .	0.3	3
75	The COVID-19 Pandemic in a Hispanic Population: A Primary Care Perspective. <i>Journal of the American Board of Family Medicine</i> , 2022, 35, 686-694.	0.8	4
76	Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies. <i>European Journal of Internal Medicine</i> , 2023, 107, 7-16.	1.0	9
77	Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	4
79	Features of the Formation of Seroprevalence to SARS-CoV2 in the Population of the Republic of Tatarstan during the Spread of COVID-19. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2023, 22, 13-21.	0.2	1
81	Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions: A retrospective observational study. <i>Global Health & Medicine</i> , 2023, , .	0.6	0